Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 354

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 354
---
     | –      |   |     |         – |     |       838 |     | –      |   |     |         – |     | –          |   |     |              838 |
| October 19 grant                 |     |         392 |     | –      |   |     |         – |     |       392 |     | –      |   |     |         – |     | –          |   |     |              392 |
| Ordinary Shares                  |     |             |     |        |   |     |           |     |           |     |        |   |     |           |     |            |   |     |                  |
| DARA Options                     |     |         138 |     | (10    | ) |     |         – |     |       128 |     | (29    | ) |     |         – |     | –          |   |     |               99 |

| F-13 |

Fair value hierarchy

The Group uses
the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1: quoted
(unadjusted) prices in active markets for identical assets and liabilities;

Level 2: other
techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly;
and

Level 3: techniques
which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

The fair value
of the Group’s derivative financial liability is measured at fair value on a recurring basis. The following table gives information
about how the fair value of this financial liability is determined.

| Schedule of fair value of this financial liability                
 Financial                                                         
 liabilities                                                       |     | Fair value as at June 30, 2024 |         |     | Fair value as        
 at December 31, 2023 |           |     | Fair value 
 hierarchy  |     | Valuation           
 technique(s)        
 and key input(s)    |     | Significant unobservable input(s)                                                                             |     | Relationship of unobservable                             
 inputs to fair value                                     |
|:------------------------------------------------------------------|:----|:-------------------------------|--------:|:----|:---------------------|----------:|:----|:-----------|:----|:--------------------|:----|:--------------------------------------------------------------------------------------------------------------|:----|:---------------------------------------------------------|
| Equity settled financial derivative liability – Series H warrants |     | £                              | 179